RecruitingEarly Phase 1NCT07274059

Allogeneic UCB-derived CAR-T for SLE

Clinical Study on the Safety and Efficacy of Allogeneic, Umbilical Cord Blood Derived CAR T-cell Therapy for Refractory Systemic Lupus Erythematosus

Sponsor

Chengdu Ucello Biotechnology Co., Ltd.

Enrollment

48 participants

Start Date

Mar 26, 2025

Study Type

INTERVENTIONAL

Conditions

SLE - Systemic Lupus Erythematosus

Summary

The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA for people with sle - systemic lupus erythematosus. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.